TY - JOUR
T1 - Effect of Collaborative Care vs Usual Care on Depressive Symptoms in Older Adults With Subthreshold Depression The CASPER Randomized Clinical Trial
AU - Gilbody, Simon
AU - Lewis, Helen
AU - Bailey, Della
AU - Atherton, Katie
AU - Birtwhistle, Jacqueline
AU - Bosanquet, Katherine
AU - Clare, Emily
AU - Delgadillo, Jaime
AU - Ekers, David
AU - Foster, Deborah
AU - Gabe, Rhian
AU - Gasgoyne, Samantha
AU - Haley, Lesley
AU - Hamilton, Jahnese
AU - Hargate, Rebecca
AU - Hewitt, Catherine
AU - Keding, Ada
AU - Holmes, John
AU - Lilley-Kelly, Amanda
AU - Meer, Shaista
AU - Mitchell, Natasha
AU - Overend, Karen
AU - Pasterfield, Madeline
AU - Pervin, Jodi
AU - Richards, David A
AU - Spilsbury, Karen
AU - Traviss-Turner, Gemma
AU - Trepel, Dominic
AU - Woodhouse, Rebecca
AU - Zeigler, Friederike
AU - McMillan, Dean
PY - 2017/2/21
Y1 - 2017/2/21
N2 - Importance There is little evidence to guide management of depressive symptoms in older people.
Objective To evaluate whether a collaborative care intervention can reduce depressive symptoms and prevent more severe depression in older people.
Design, Setting, and Participants Randomized clinical trial conducted from May 24, 2011, to November 14, 2014, in 32 primary care centers in the United Kingdom among 705 participants aged 65 years or older with Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) sub threshold depression; participants were followed up for 12 months.
Interventions Collaborative care (n=344) was coordinated by a case manager who assessed functional impairments relating to mood symptoms. Participants were offered behavioral activation and completed an average of 6 weekly sessions. The control group received usual primary care (n=361).
Main Outcomes and Measures The primary outcome was self-reported depression severity at 4-month follow-up on the 9-item Patient Health Questionnaire (PHQ-9; score range, 0-27). Included among 10 prespecified secondary outcomes were the PHQ-9 score at 12-month follow-up and the proportion meeting criteria for depressive disorder (PHQ-9 score ≥10) at 4- and 12-month follow-up.
Results The 705 participants were 58% female with a mean age of 77 (SD, 7.1) years. Four-month retention was 83%, with higher loss to follow-up in collaborative care (82/344 [24%]) vs usual care (37/361 [10%]). Collaborative care resulted in lower PHQ-9 scores vs usual care at 4-month follow-up (mean score with collaborative care, 5.36 vs with usual care, 6.67; mean difference, −1.31; 95% CI, −1.95 to −0.67; P < .001). Treatment differences remained at 12 months (mean PHQ-9 score with collaborative care, 5.93 vs with usual care, 7.25; mean difference, −1.33; 95% CI, −2.10 to −0.55). The proportions of participants meeting criteria for depression at 4-month follow-up were 17.2% (45/262) vs 23.5% (76/324), respectively (difference, −6.3% [95% CI, −12.8% to 0.2%]; relative risk, 0.83 [95% CI, 0.61-1.27]; P = .25) and at 12-month follow-up were 15.7% (37/235) vs 27.8% (79/284) (difference, −12.1% [95% CI, −19.1% to −5.1%]; relative risk, 0.65 [95% CI, 0.46-0.91]; P = .01).
Conclusions and Relevance Among older adults with subthreshold depression, collaborative care compared with usual care resulted in a statistically significant difference in depressive symptoms at 4-month follow-up, of uncertain clinical importance. Although differences persisted through 12 months, findings are limited by attrition, and further research is needed to assess longer-term efficacy.
Trial Registration isrctn.org Identifier: ISRCTN02202951
AB - Importance There is little evidence to guide management of depressive symptoms in older people.
Objective To evaluate whether a collaborative care intervention can reduce depressive symptoms and prevent more severe depression in older people.
Design, Setting, and Participants Randomized clinical trial conducted from May 24, 2011, to November 14, 2014, in 32 primary care centers in the United Kingdom among 705 participants aged 65 years or older with Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) sub threshold depression; participants were followed up for 12 months.
Interventions Collaborative care (n=344) was coordinated by a case manager who assessed functional impairments relating to mood symptoms. Participants were offered behavioral activation and completed an average of 6 weekly sessions. The control group received usual primary care (n=361).
Main Outcomes and Measures The primary outcome was self-reported depression severity at 4-month follow-up on the 9-item Patient Health Questionnaire (PHQ-9; score range, 0-27). Included among 10 prespecified secondary outcomes were the PHQ-9 score at 12-month follow-up and the proportion meeting criteria for depressive disorder (PHQ-9 score ≥10) at 4- and 12-month follow-up.
Results The 705 participants were 58% female with a mean age of 77 (SD, 7.1) years. Four-month retention was 83%, with higher loss to follow-up in collaborative care (82/344 [24%]) vs usual care (37/361 [10%]). Collaborative care resulted in lower PHQ-9 scores vs usual care at 4-month follow-up (mean score with collaborative care, 5.36 vs with usual care, 6.67; mean difference, −1.31; 95% CI, −1.95 to −0.67; P < .001). Treatment differences remained at 12 months (mean PHQ-9 score with collaborative care, 5.93 vs with usual care, 7.25; mean difference, −1.33; 95% CI, −2.10 to −0.55). The proportions of participants meeting criteria for depression at 4-month follow-up were 17.2% (45/262) vs 23.5% (76/324), respectively (difference, −6.3% [95% CI, −12.8% to 0.2%]; relative risk, 0.83 [95% CI, 0.61-1.27]; P = .25) and at 12-month follow-up were 15.7% (37/235) vs 27.8% (79/284) (difference, −12.1% [95% CI, −19.1% to −5.1%]; relative risk, 0.65 [95% CI, 0.46-0.91]; P = .01).
Conclusions and Relevance Among older adults with subthreshold depression, collaborative care compared with usual care resulted in a statistically significant difference in depressive symptoms at 4-month follow-up, of uncertain clinical importance. Although differences persisted through 12 months, findings are limited by attrition, and further research is needed to assess longer-term efficacy.
Trial Registration isrctn.org Identifier: ISRCTN02202951
U2 - doi:10.1001/jama.2017.0130
DO - doi:10.1001/jama.2017.0130
M3 - Article
SN - 0002-9955
VL - 317
SP - 728
EP - 737
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
IS - 7
ER -